Related Experiment Video

Updated: Jan 6, 2026

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics
04:01

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Published on: March 15, 2024

1.8K

Inhibition of MID1IP1 induces ferroptosis and suppresses c-Myc expression in colorectal cancer cell

Je Joung Oh1, Yu Jin Lee1, Yeo Jeong Han1

  • 1College of Korean Medicine, Kyung Hee University, Seoul, 02447, Korea.

Genes & Genomics
|December 4, 2025
PubMed
Abstract

Insights

Midline 1 Interacting Protein 1 (MID1IP1) promotes colorectal cancer (CRC) survival by stabilizing c-Myc and preventing ferroptosis. Targeting MID1IP1 may offer new therapeutic strategies for CRC treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Colorectal cancer (CRC) is a leading global cancer diagnosis.
  • Drug resistance and metastasis remain significant challenges in CRC treatment.
  • Midline 1 Interacting Protein 1 (MID1IP1) expression correlates with tumor growth via c-Myc.

Purpose of the Study:

  • Investigate MID1IP1's role in CRC metabolic reprogramming.
  • Determine MID1IP1's effect on ferroptosis and cell migration in CRC.
  • Explore the link between MID1IP1, c-Myc, and CRC progression.

Main Methods:

  • MID1IP1 was silenced in HCT116 cells using siRNA.
  • Assays included colony formation, Western blotting, ROS measurement, and wound healing.
  • Proteins assessed included c-Myc, ferroptosis markers, glycolytic enzymes, and EMT markers.

Main Results:

  • MID1IP1 knockdown reduced cell growth and c-Myc stability.
  • Glycolysis and ferroptosis-protective proteins decreased, leading to ROS accumulation and ferroptosis.
  • Cell migration was inhibited, with associated changes in EMT markers.

Conclusions:

  • MID1IP1 enhances CRC cell survival by stabilizing c-Myc and inhibiting ferroptosis.
  • MID1IP1 influences CRC cell migration and metabolic reprogramming.
  • MID1IP1 presents a potential novel biomarker and therapeutic target for CRC.
Keywords:
Colorectal cancerFerroptosisMID1IP1Warburg effectc-Myc

More Related Videos

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.7K
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.6K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
5.3K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.7K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
23.8K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.6K